Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia - HTA report (main)

The research question addressed by this report is, “What is the clinical effectiveness and costeffectiveness of fludarabine in B-cell CLL with sufficient bone marrow reserve and who have not responded to or whose disease has progressed during or after treatment with at least one standard alkylating-agent containing regimen?” these being the circumstances for which fludarabine is currently licensed.

This page was last updated: 30 March 2010